Osteoporosis.
2011 Apr;9(1):132-138.
The Study of Bisphosphonate and Postmenopausal Hormone Treatment in Low Bone Mineral Density
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Medical School, Chosun University, Gwangju, Korea.
- 2Department of Obstetrics and Gynecology, College of Medicine, Wonkwang University, Gunpo, Korea. bimilo@hanmail.net
- 3Department of Obstetrics and Gynecology, Haeundae Paik Hospital, Inje university, Busan, Korea.
- 4Department of Obstetrics and Gynecology, Kosin University, Busan, Korea.
- 5Department of Family Medicine, Kosin University, Busan, Korea.
- 6Department of Obstetrics and Gynecology, School of Medicine, Gyeongsang National University, Jinju, Korea.
- 7Department of Obstetrics and Gynecology, Kyung Hee Medical Center, Kyung Hee University, Seoul, Korea.
- 8Department of Obstetrics and Gynecology, School of Medicine, Konkuk University, Seoul, Korea.
Abstract
OBJECTIVES
To evaluate the effect of postmenopausal hormone therapy alone or in combination with bisphosphonate on bone mineral density (BMD) in postmenopausal women.
METHODS
One hundred three women diagnosed with low BMD in postmenopausal women were included in this study. All patients were classified into two groups; oarl hormone therpy alone (Group I) or with alendronate (Group II), given for 12 months. Dual energy X-ray absorptiometry was used to measure BMD before and after 12 months of treatment.
RESULTS
In all groups, significant increase in bone density measurements were seen at 12 months of treatment. The BMD of lumbar spine more increased significantly in Group II than Group I.
CONCLUSIONS
Postmenopausal hormone therapy is effective in osteopenic and osteoporotic women. However, the combined treatment with hormone therapy and bisphophonate is more effective in postmenopausal women with low BMD.